{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-23-000050","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.265278+00:00","generated_at":"2026-06-15T09:33:04.412316+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH","bullets":["Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.","Cash, equivalents and marketable securities of $201.9M as of March 31, 2023; expected to fund operations through at least 12 months.","Phase 3 registrational trial of seralutinib in PAH planned for 3Q23; FDA and EMA feedback on key design elements received.","Operational restructuring: headcount reduced by over 25%; all other clinical/preclinical programs terminated.","Initial open-label extension data from TORREY study expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-23-000050","json":"https://secwatch.observer/filing/0001728117-23-000050.json","markdown":"https://secwatch.observer/filing/0001728117-23-000050.md","text":"https://secwatch.observer/filing/0001728117-23-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/0001728117-23-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/goss-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T09:33:04.412316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"016df3a134eabd9206f7d4b2b9c6ff53c2808ad8","claim":"Gossamer Bio, Inc. reported the quarter ended March 31, 2023 results: net income Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share.","evidence_excerpt":"On May 9, 2023, Gossamer Bio, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728117/000172811723000050/0001728117-23-000050-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss for the quarter ended March 31, 2023, was $49.2 million, or $0.52 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}